World experts on leukodystrophies were brought together by ELA International to push research forward.

ELA International has brought together eminent researchers from different countries (United States, Germany, the Netherlands, France,etc.) December 2 and 3 in Luxembourg to enrich their mutual approaches to leukodystrophies, and thus advance research.

The symposium, placed under the High Patronage of Her Royal Highness the Grand Duchess, was inaugurated by Guy Alba Founder of ELA and Chairman of the Board of ELA International, in the presence of the Presidents of ELA Belgium, ELA Germany, ELA Italy, and members of ELA International’s Scientific Council and Ethics Committee. Three priority themes were addressed during the symposium:

• Newborn screening and diagnostic biomarkers of leukodystrophies
• Clinical trial design and real-world data inclusion
• Pelizaeus-Merzbacher Disease (PMD) news

At the symposium, ELA International announced the opening in spring 2025 of an exceptional call for tenders, funded to the tune of €500,000, to launch a research project dedicated to Pelizaeus-Merzbacher disease (PMD). PMD is a hypomyelinating leukodystrophy with abnormal myelin development caused by X-linked mutations in the PLP1 gene.